Axsome Therapeutics: Valuation Check Amid Recent Share Price Decline

Axsome Therapeutics (AXSM) share price has cooled after recent trading, closing at $156.35. Despite mixed returns over the past week, month, and 3 months, investors are weighing its focus on CNS treatments, $7.998b market value, and annual revenue of $638.496 million alongside a net loss of $183.174 million. The company is advancing multiple late-stage clinical programs, positioning it to benefit from the aging population and rising prevalence of CNS disorders. The most followed narrative pegs Axsome's fair value at about $222.47, implying a valuation gap in favor of the current price.